CR20180365A - PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS - Google Patents
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOSInfo
- Publication number
- CR20180365A CR20180365A CR20180365A CR20180365A CR20180365A CR 20180365 A CR20180365 A CR 20180365A CR 20180365 A CR20180365 A CR 20180365A CR 20180365 A CR20180365 A CR 20180365A CR 20180365 A CR20180365 A CR 20180365A
- Authority
- CR
- Costa Rica
- Prior art keywords
- tl1a
- antigen
- tnf
- binding proteins
- antigen binding
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000025171 antigen binding proteins Human genes 0.000 abstract 5
- 108091000831 antigen binding proteins Proteins 0.000 abstract 5
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 abstract 3
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 abstract 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Ecology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención hace referencia a proteínas de unión al antígeno que se unen a TL1A, inclusive proteínas de unión al antígeno biespecífico (p. ej., anticuerpos) a TL1A y TNF-a. Dichos anticuerpos biespecíficos pueden estar en un formato de inmunoglobulina tetramérica, en el cual un par de cadena pesada-cadena ligera del anticuerpo se dirige al TL1A y el otro a TNF-a. Las proteínas de unión al antígeno biespecífico pueden estar incluidas también en una fusión de IgG-scFv, donde un anticuerpo tetramérico convencional dirigido a un antígeno se fusiona con un par de unidades Fv de cadena simple dirigido al otro. La proteína de unión al antígeno biespecífico se puede incluir también en una fusión de IgG-Fab, en la que una molécula Fab que se une a un antígeno se fusiona con cada cadena pesada de un anticuerpo tetramérico convencional dirigido al otro antígeno. La invención hace referencia también a los usos de las proteínas de unión a anti-TL1A y las proteínas de unión al antígeno de anti-TL1A/anti-TNF-a y las formulaciones farmacéuticas de estas.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562268432P | 2015-12-16 | 2015-12-16 | |
| US201662333063P | 2016-05-06 | 2016-05-06 | |
| PCT/US2016/052006 WO2017049004A1 (en) | 2015-09-15 | 2016-09-15 | Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof |
| PCT/US2016/066722 WO2017106383A1 (en) | 2015-12-16 | 2016-12-14 | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20180365A true CR20180365A (es) | 2018-09-28 |
Family
ID=59057540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20180365A CR20180365A (es) | 2015-12-16 | 2016-09-15 | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11104745B2 (es) |
| EP (2) | EP4640705A2 (es) |
| JP (1) | JP7263007B2 (es) |
| KR (1) | KR20180099723A (es) |
| CN (1) | CN109311971B (es) |
| AU (2) | AU2016370659B2 (es) |
| BR (1) | BR112018012096A2 (es) |
| CA (1) | CA3008267A1 (es) |
| CL (3) | CL2018001596A1 (es) |
| CO (1) | CO2018007355A2 (es) |
| CR (1) | CR20180365A (es) |
| EA (1) | EA201891322A1 (es) |
| FI (1) | FI3390444T3 (es) |
| IL (2) | IL314885A (es) |
| JO (1) | JO3816B1 (es) |
| MA (1) | MA44060A (es) |
| MX (1) | MX2018007424A (es) |
| MY (1) | MY205021A (es) |
| PH (1) | PH12018501284A1 (es) |
| SG (2) | SG10201912002YA (es) |
| TN (1) | TN2019000275A1 (es) |
| TW (1) | TWI799368B (es) |
| UA (1) | UA124305C2 (es) |
| UY (1) | UY37027A (es) |
| WO (1) | WO2017106383A1 (es) |
| ZA (2) | ZA201904491B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
| MX2014003689A (es) | 2011-09-30 | 2014-12-05 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos contra tl1a y sus usos. |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| EP3639841B1 (en) | 2013-03-27 | 2023-09-06 | Cedars-Sinai Medical Center | Treating fibrosis by inhibiting tl1a |
| JP6482533B2 (ja) | 2013-05-17 | 2019-03-13 | セダーズ−シナイ メディカル センター | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
| EP4105236A1 (en) | 2013-07-19 | 2022-12-21 | Cedars-Sinai Medical Center | Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| EP3430172A4 (en) | 2016-03-17 | 2019-08-21 | Cedars-Sinai Medical Center | METHOD FOR DIAGNOSIS OF INFLAMMATORY ENDURANCE THROUGH RNASET2 |
| MY191324A (en) | 2016-10-26 | 2022-06-15 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| WO2019005641A1 (en) * | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF |
| EP3456738B1 (en) * | 2017-09-19 | 2024-07-17 | Tillotts Pharma Ag | Antibody variants |
| MA51523A (fr) * | 2018-01-05 | 2020-11-11 | Modernatx Inc | Polynucléotides codant pour des anticorps anti-virus du chikungunya |
| US20210070871A1 (en) | 2018-04-25 | 2021-03-11 | Prometheus Biosciences, Inc. | Optimized anti-tl1a antibodies |
| CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
| CA3140029A1 (en) | 2019-05-14 | 2020-11-19 | Prometheus Biosciences, Inc. | Tl1a patient selection methods, systems, and devices |
| EP3998286A4 (en) * | 2019-07-11 | 2023-04-26 | Wuhan Yzy Biopharma Co., Ltd. | QUAD VALUE SYMMETRIC BISPECIFIC ANTIBODIES |
| CN114423787B (zh) | 2019-07-19 | 2025-01-24 | 昂科里斯庞斯公司 | 免疫调节性抗体及其使用方法 |
| EP4025240B1 (en) * | 2019-09-03 | 2024-10-30 | Amgen Inc. | Il-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof |
| EP4048309A4 (en) | 2019-10-24 | 2024-02-21 | Prometheus Biosciences, Inc. | HUMANIZED ANTIBODIES AGAINST TNF-LIKE LIGAND 1A (TL1A) AND THEIR USES |
| CN113121696A (zh) * | 2019-12-31 | 2021-07-16 | 周易 | Fab改造诱导形成的双特异性抗体及其制备方法和用途 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| US20230159649A1 (en) * | 2020-04-02 | 2023-05-25 | La Jolla Institute For Immunology | Methods and combinations for dual targeting of tnf family members |
| KR20230024904A (ko) * | 2020-05-20 | 2023-02-21 | 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 | Sars-cov-2에 대한 강력한 중화 항체, 그의 생성 및 용도 |
| JP2023534922A (ja) | 2020-07-06 | 2023-08-15 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | ＳＡＲＳ－ＣｏＶ－２を標的とする抗原結合分子 |
| WO2022010921A1 (en) | 2020-07-06 | 2022-01-13 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
| CN116348487A (zh) | 2020-07-23 | 2023-06-27 | 欧萨尔普罗席纳有限公司 | 抗淀粉样β抗体 |
| CA3191710A1 (en) * | 2020-08-20 | 2022-02-24 | Amgen Inc. | Antigen binding proteins with non-canonical disulfide in fab region |
| WO2022047033A1 (en) | 2020-08-26 | 2022-03-03 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
| BR112023009172A2 (pt) * | 2020-11-13 | 2023-10-03 | Cedars Sinai Medical Center | Métodos, sistemas e kits para tratamento de doenças inflamatórias direcionados à tl1a |
| EP4326772A4 (en) * | 2021-04-23 | 2025-03-05 | Chimagen Biosciences, Ltd. | Heterodimeric antibodies and antigen-binding fragment thereof |
| AU2024324300A1 (en) | 2023-08-11 | 2026-02-12 | Paragon Therapeutics, Inc. | Tl1a binding antibodies and methods of use |
| TW202535949A (zh) | 2023-12-20 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 靶向IL-18受體β(IL-18RB)之抗體及相關方法 |
| TW202542181A (zh) * | 2023-12-26 | 2025-11-01 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 特異性結合類ｔｎｆ配體１ａ（ｔｌ１ａ）之單株抗體或其抗原結合片段及其用途 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
| DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| JP3202999B2 (ja) | 1991-01-31 | 2001-08-27 | 協和醗酵工業株式会社 | 肝移行性リポソーム製剤 |
| US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
| US7820798B2 (en) | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク． | 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
| ATE356630T1 (de) | 1998-04-03 | 2007-04-15 | Univ Iowa Res Found | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
| NZ592550A (en) | 1999-03-25 | 2012-12-21 | Abbott Gmbh & Co Kg | Compostion comprising antibody capable of binding to p40 subunit of IL-12 |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| EP1210435A1 (en) | 1999-08-04 | 2002-06-05 | Amgen Inc. | Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY |
| EP1578799B8 (en) | 2002-12-02 | 2011-03-23 | Amgen Fremont Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
| EP1667730B1 (en) | 2003-08-20 | 2013-06-26 | University of Miami | Compositions and methods for treating inflammatory lung disease |
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20110217310A1 (en) | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
| CA2705292C (en) | 2007-11-13 | 2016-06-21 | Teva Biopharmaceuticals Usa, Inc. | Humanized antibodies against tl1a |
| AU2009204501B2 (en) | 2008-01-07 | 2015-02-12 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
| WO2009131239A1 (ja) | 2008-04-25 | 2009-10-29 | Kyowa Hakko Kirin Co Ltd | 安定な多価抗体 |
| CA2757669A1 (en) | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Bispecific anti-erbb-1/anti-c-met antibodies |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| UY33827A (es) | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión a media-inmunoglobulina y sus usos |
| UY33826A (es) | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión con dominios trivariables y sus usos |
| CA2836898A1 (en) | 2011-05-20 | 2012-11-29 | Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
| EP2758438A1 (en) | 2011-09-23 | 2014-07-30 | Amgen Research (Munich) GmbH | Bispecific binding molecules for 5t4 and cd3 |
| MX2014003689A (es) | 2011-09-30 | 2014-12-05 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos contra tl1a y sus usos. |
| WO2013177101A2 (en) | 2012-05-22 | 2013-11-28 | Bristol-Myers Squibb Company | Bispecific antibodies and methods of using the same |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| KR102545617B1 (ko) | 2012-11-28 | 2023-06-20 | 자임워크스 비씨 인코포레이티드 | 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도 |
| MX360155B (es) | 2013-01-02 | 2018-10-24 | Glenmark Pharmaceuticals Sa | Anticuerpos que se unen al ligando 1a tipo tnf y sus usos. |
| TW201444867A (zh) | 2013-03-08 | 2014-12-01 | Lilly Co Eli | 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體 |
| PH12022550138A1 (en) | 2013-03-13 | 2023-03-06 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
| US9546203B2 (en) | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| WO2014144357A1 (en) | 2013-03-15 | 2014-09-18 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
| BR112015023752B1 (pt) * | 2013-03-15 | 2023-11-14 | Zyngenia, Inc. | Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo |
| UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| CN113150144A (zh) | 2013-11-13 | 2021-07-23 | 辉瑞大药厂 | 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途 |
| US20160052006A1 (en) | 2013-11-22 | 2016-02-25 | Sheila S. Pirtle | Spray Bottle |
-
2016
- 2016-09-15 CR CR20180365A patent/CR20180365A/es unknown
- 2016-12-14 CN CN201680082044.0A patent/CN109311971B/zh active Active
- 2016-12-14 WO PCT/US2016/066722 patent/WO2017106383A1/en not_active Ceased
- 2016-12-14 TN TNP/2019/000275A patent/TN2019000275A1/en unknown
- 2016-12-14 US US16/062,096 patent/US11104745B2/en active Active
- 2016-12-14 CA CA3008267A patent/CA3008267A1/en active Pending
- 2016-12-14 SG SG10201912002YA patent/SG10201912002YA/en unknown
- 2016-12-14 EA EA201891322A patent/EA201891322A1/ru unknown
- 2016-12-14 BR BR112018012096-0A patent/BR112018012096A2/pt active Search and Examination
- 2016-12-14 UA UAA201806971A patent/UA124305C2/uk unknown
- 2016-12-14 SG SG11201804857WA patent/SG11201804857WA/en unknown
- 2016-12-14 MA MA044060A patent/MA44060A/fr unknown
- 2016-12-14 JP JP2018531447A patent/JP7263007B2/ja active Active
- 2016-12-14 IL IL314885A patent/IL314885A/en unknown
- 2016-12-14 AU AU2016370659A patent/AU2016370659B2/en active Active
- 2016-12-14 MY MYPI2018000910A patent/MY205021A/en unknown
- 2016-12-14 EP EP25197682.5A patent/EP4640705A2/en active Pending
- 2016-12-14 MX MX2018007424A patent/MX2018007424A/es unknown
- 2016-12-14 EP EP16822583.7A patent/EP3390444B1/en active Active
- 2016-12-14 FI FIEP16822583.7T patent/FI3390444T3/fi active
- 2016-12-14 KR KR1020187020093A patent/KR20180099723A/ko not_active Ceased
- 2016-12-15 UY UY0001037027A patent/UY37027A/es active IP Right Grant
- 2016-12-15 JO JOP/2016/0261A patent/JO3816B1/ar active
- 2016-12-16 TW TW105141920A patent/TWI799368B/zh active
-
2018
- 2018-06-06 IL IL259847A patent/IL259847A/en unknown
- 2018-06-14 CL CL2018001596A patent/CL2018001596A1/es unknown
- 2018-06-14 PH PH12018501284A patent/PH12018501284A1/en unknown
- 2018-07-13 CO CONC2018/0007355A patent/CO2018007355A2/es unknown
-
2019
- 2019-07-09 ZA ZA2019/04491A patent/ZA201904491B/en unknown
-
2020
- 2020-05-27 ZA ZA2020/03133A patent/ZA202003133B/en unknown
-
2021
- 2021-05-05 CL CL2021001179A patent/CL2021001179A1/es unknown
-
2023
- 2023-09-01 CL CL2023002597A patent/CL2023002597A1/es unknown
-
2024
- 2024-01-29 AU AU2024200534A patent/AU2024200534A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023002597A1 (es) | Proteínas de unión al antígeno bispecífico de anti-tl1a/anti-tnf-alfa | |
| DOP2018000259A (es) | Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral | |
| CR20170383A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| DOP2021000005A (es) | Proteínas de unión a pd1 y/o lag3 | |
| CY1124691T1 (el) | Διειδικα αντισωματα ειδικα για pd1 και τιμ3 | |
| CO2019003945A2 (es) | Proteínas de fusión heterodiméricas biespecíficas que contienen proteínas de fusión fc il-15/il-15rα y fragmentos de anticuerpo pd-1 | |
| CL2018001326A1 (es) | Proteínas de unión a ctla4. | |
| CL2019000082A1 (es) | Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso. | |
| MX2022006461A (es) | Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos. | |
| AR106555A1 (es) | Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas | |
| CR20170026A (es) | Anticuerpos anti-tau humanizados | |
| MX2018004721A (es) | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. | |
| PE20141995A1 (es) | Moleculas que son anticuerpos con especificidad por ox 40 humano | |
| PE20151289A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| MX2016000721A (es) | Direccionamiento de antagonistas de citocinas. | |
| MX394735B (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
| CO2019003759A2 (es) | Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos | |
| MX2015009819A (es) | Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo. | |
| CO2021008755A2 (es) | Anticuerpo que se une a vegf y a il-1beta y métodos de utilización | |
| CL2021001104A1 (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
| AR107075A1 (es) | PROTEÍNAS DE UNIÓN AL ANTÍGENO BIESPECÍFICO DE ANTI-TL1A / ANTI-TNF-a Y SUS USOS |